Nabi Biopharmaceuticals’s ( NABI) share price has entered into oversold territory with a stochastic value of 15.55. The Zacks Consensus Estimate on the company’s earnings for 2010 increased by 22 cents over the past month to 14 cents per share. Nabi Biopharmaceuticals is a Zacks #1 Rank (“Strong Buy”) company.
 
NABI BIOPHARMA (NABI): Free Stock Analysis Report
 
Zacks Investment Research